97 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp02379 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 91.8% cell viability at 12.5 µM |
| dbacp02380 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 84.1% cell viability at 25 µM |
| dbacp02381 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 76.3% cell viability at 50 µM |
| dbacp02382 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 71.5 % cell viability at 75 µM |
| dbacp02383 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 54.2 % cell viability at 100 µM |
| dbacp02384 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 87.3 % cell viability at 25 µM |
| dbacp02385 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 75.6 % cell viability at 50 µM |
| dbacp02386 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 62.8 % cell viability at 75 µM |
| dbacp02387 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 54.3 % cell viability at 100 µM |
| dbacp02388 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 48.6 % cell viability at 100 µM |
| dbacp02389 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 72.1 % cell viability at 12.5 µM |
| dbacp02390 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 63.3 % cell viability at 25 µM |
| dbacp02391 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 49.7 % cell viability at 50 µM |
| dbacp02392 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 41.1 % cell viability at 75 µM |
| dbacp02393 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 35.2 % cell viability at 100 µM |
| dbacp04487 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : >150 µg/ml |
| dbacp04488 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | 8402 | Leukemia cancer | IC50 : >150 µg/ml |
| dbacp04489 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | SSKT-1 | Hematopoietic cancer | IC50 : >150 µg/ml |
| dbacp04490 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Daudi | Colon cancer | IC50 : >150 µg/ml |
| dbacp04491 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MLA | Leukemia cancer | IC50 : >150 µg/ml |
| dbacp04492 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Raji | Lymphoma cancer | IC50 : >150 µg/ml |
| dbacp04493 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | K-562 | Leukemia cancer | IC50 : >150 µg/ml |
| dbacp04494 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | CHP-100 | Ewing sarcoma | IC50 : >200 µg/ml |
| dbacp04495 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MCF-7 | Breast cancer | IC50 : >200 µg/ml |
| dbacp04496 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | IC50 : >200 µg/ml |
| dbacp04505 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 16 µg/ml |
| dbacp04506 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | 8402 | Leukemia cancer | IC50 : 18 µg/ml |
| dbacp04507 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | SSKT-1 | Hematopoietic cancer | IC50 : 23 µg/ml |
| dbacp04508 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Daudi | Lung cancer | IC50 : 30 µg/ml |
| dbacp04509 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MLA | Leukemia cancer | IC50 : 34 µg/ml |
| dbacp04510 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Raji | Lymphoma cancer | IC50 : 20 µg/ml |
| dbacp04511 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | K-562 | Leukemia cancer | IC50 : 40 µg/ml |
| dbacp04512 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | CHP-100 | Ewing sarcoma | IC50 : 45 µg/ml |
| dbacp04513 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MCF-7 | Breast cancer | IC50 : 49 µg/ml |
| dbacp04514 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | IC50 : 53 µg/ml |
| dbacp04515 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 17 µg/ml |
| dbacp04516 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | 8402 | Leukemia cancer | IC50 : 12 µg/ml |
| dbacp04517 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | SSKT-1 | Hematopoietic cancer | IC50 : 27 µg/ml |
| dbacp04518 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Daudi | Ovarian cancer | IC50 : 28 µg/ml |
| dbacp04519 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MLA | Leukemia cancer | IC50 : 30 µg/ml |
| dbacp04520 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Raji | Lymphoma cancer | IC50 : 23 µg/ml |
| dbacp04521 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | K-562 | Leukemia cancer | IC50 : 32 µg/ml |
| dbacp04522 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | CHP-100 | Ewing sarcoma | IC50 : 32 µg/ml |
| dbacp04523 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MCF-7 | Breast cancer | IC50 : 37 µg/ml |
| dbacp04524 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | IC50 : 41 µg/ml |
| dbacp04531 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 19 µg/ml |
| dbacp04532 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | 8402 | Leukemia cancer | IC50 : 16 µg/ml |
| dbacp04533 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | SSKT-1 | Hematopoietic cancer | IC50 : 29 µg/ml |
| dbacp04534 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Daudi | Renal cancer | IC50 : 38 µg/ml |
| dbacp04535 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MLA | Leukemia cancer | IC50 : 33 µg/ml |
| dbacp04536 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Raji | Lymphoma cancer | IC50 : 25 µg/ml |
| dbacp04537 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | K-562 | Leukemia cancer | IC50 :37 µg/ml |
| dbacp04538 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | CHP-100 | Ewing sarcoma | IC50 : 39 µg/ml |
| dbacp04539 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MCF-7 | Breast cancer | IC50 : 42 µg/ml |
| dbacp04540 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | IC50 : 47 µg/ml |
| dbacp05743 | PTPRJ-pep19 | CHHNLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 4.5 ± 0.1.4% cell growth inhibition at 160 µM |
| dbacp05744 | PTPRJ-pep19 | CHHNLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 19 ± 2.82% cell growth inhibition at 160 µM |
| dbacp05745 | PTPRJ-pep19.0 | CHHNLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 4 ± 1.4% cell growth inhibition at 160 µM |
| dbacp05746 | PTPRJ-pep19.2 | CAHNLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 16.5 ± 2.12% cell growth inhibition at 160 µM |
| dbacp05747 | PTPRJ-pep19.2 | CAHNLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 30 ± 2.82% cell growth inhibition at 160 µM |
| dbacp05748 | PTPRJ-pep19.2 | CAHNLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 32.0 ± 4.2% cell growth inhibition at 160 µM |
| dbacp05749 | PTPRJ-pep19.3 | CHANLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 28 ± 5.5% cell growth inhibition at 160 µM |
| dbacp05750 | PTPRJ-pep19.3 | CHANLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 46 ± 4.2% cell growth inhibition at 160 µM |
| dbacp05751 | PTPRJ-pep19.3 | CHANLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 51 ± 1.4% cell growth inhibition at 160 µM |
| dbacp05752 | PTPRJ-pep19.4 | CHHALTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 48.0 ± 2.82% cell growth inhibition at 160 µM |
| dbacp05753 | PTPRJ-pep19.4 | CHHALTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 62.5 ± 4.9% cell growth inhibition at 160 µM |
| dbacp05754 | PTPRJ-pep19.4 | CHHALTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 66.5 ± 2.12% cell growth inhibition at 160 µM |
| dbacp05755 | PTPRJ-pep19.5 | CHHNATHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 2 ± 1.5% cell growth inhibition at 160 µM |
| dbacp05756 | PTPRJ-pep19.5 | CHHNATHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 19 ± 4.2% cell growth inhibition at 160 µM |
| dbacp05757 | PTPRJ-pep19.6 | CHHNLAHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 19 ± 4.2% cell growth inhibition at 160 µM |
| dbacp05758 | PTPRJ-pep19.7 | CHHNLTAAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 4.5 ± 2.13% cell growth inhibition at 160 µM |
| dbacp05759 | PTPRJ-pep19.7 | CHHNLTAAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 20 ± 1.4% cell growth inhibition at 160 µM |
| dbacp06557 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 123 µg/ml |
| dbacp06558 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | 8402 | Leukemia cancer | IC50 : 83 µg/ml |
| dbacp06559 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | SSKT-1 | Hematopoietic cancer | IC50 : 109 µg/ml |
| dbacp06560 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Daudi | Leukemia cancer | IC50 : 143 µg/ml |
| dbacp06561 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MLA | Leukemia cancer | IC50 : 102 µg/ml |
| dbacp06562 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Raji | Lymphoma cancer | IC50 : 72 µg/ml |
| dbacp06563 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | K-562 | Leukemia cancer | IC50 : 112 µg/ml |
| dbacp06564 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | CHP-100 | Ewing sarcoma | Not found |
| dbacp06565 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MCF-7 | Breast cancer | Not found |
| dbacp06566 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | Not found |
| dbacp06573 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 97 µg/ml |
| dbacp06574 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | 8402 | Leukemia cancer | IC50 : 60 µg/ml |
| dbacp06575 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | SSKT-1 | Hematopoietic cancer | IC50 : 107 µg/ml |
| dbacp06576 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | Daudi | Brain tumor | IC50 : 115 µg/ml |
| dbacp06577 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | MLA | Leukemia cancer | IC50 : 80 µg/ml |
| dbacp06578 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | Raji | Lymphoma cancer | IC50 : 64 µg/ml |
| dbacp06579 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | K-562 | Leukemia cancer | IC50 : 98 µg/ml |
| dbacp06580 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | CHP-100 | Ewing sarcoma | Not found |
| dbacp06581 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | MCF-7 | Breast cancer | Not found |
| dbacp06582 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | Not found |
| dbacp06773 | Moricin | AKIPIKAAIKTVGKAVGKGLRAINIASTANDVFNFLKPKKRKA | Bombyx mori | Peptide-induced cell death | Trypan blue assay | MDA-MB-231 | Triple-negative Breast Cancer | 70% cell viability at 6.25 µg/ml |
| dbacp07343 | HMP-S7 | SFIPRAKSTWLNNIKLL | Human Milk | Membrane penetration, cytoplasmic leakage | Trypan blue assay | Jurkat | Blood Cancer | IC50 = 186 ± 37 µM |
| dbacp07344 | HMP-S7 | SFIPRAKSTWLNNIKLL | Human Milk | Membrane penetration, cytoplasmic leakage | Trypan blue assay | RS4 | Blood Cancer | IC50 = 184 ± 23 µM |
| dbacp07345 | HMP-S7 | SFIPRAKSTWLNNIKLL | Human Milk | Membrane penetration, cytoplasmic leakage | Trypan blue assay | Raji | Lymphoma Cancer | IC50 = 89 ± 24 µM |
| dbacp07346 | HMP-S7 | SFIPRAKSTWLNNIKLL | Human Milk | Membrane penetration, cytoplasmic leakage | Trypan blue assay | Sup-B15 | Blood Cancer | IC50 = 90 ± 14 µM |